Lexicon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview

* Lexicon Pharmaceuticals Inc is expected to show a rise in quarterly revenue when it reports results on November 6 (estimated) for the period ending September 30 2024

* The The Woodlands Texas-based company is expected to report a 1,708.3% increase in revenue to $2.93 million from $162 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for Lexicon Pharmaceuticals Inc is for a loss of 16 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is 5.00​, above​ its last closing price of $1.22. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -0.19 -0.19 -0.17 Beat 9.9

Mar. 31 2024 -0.20 -0.20 -0.20 Met -1.3

Dec. 31 2023 -0.22 -0.22 -0.20 Beat 7.9​

Sep. 30 2023 -0.21 -0.21 -0.21 Met 2.2

​​Jun. -0.17 -0.17 -0.22 Missed -25.9

30 2023

Mar. 31 2023 -0.18 -0.18 -0.17 Beat 5.2​

Dec. 31 2022 -0.14 -0.13 -0.16 Missed -19.4

Sep. 30 2022 -0.14 -0.14 -0.13 Beat 6.7

This summary was machine generated November 4 at 15:37 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)